A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 2

Conditions: Generalized Anxiety Disorder

Treatments: Drug: MK0777; Drug: Placebo (unspecified)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00703833

0777-019

2007_630

MK0777-019

Details and patient eligibility

About

The study will look at the effectiveness of MK0777 in patients with Generalized Anxiety Disorder.

Enrollment: 51 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or Female
• Current diagnosis of Generalized Anxiety Disorder
• Age 18 - 70

Exclusion criteria

• Women who are pregnant, or breast-feeding
• Use of illicit drugs
• History of drug or alcohol dependence

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

51 participants in 2 patient groups, including a placebo group

1

Experimental group

Description:

Drug

Treatment:

Drug: MK0777

2

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Placebo (unspecified)